*Refresh the page if the below document does not appear.
Medley Pharma and Cipla called off deal over valuation mismatch issues
Medley Pharmaceuticals called off its sale after a conversation with its lead prospect Cipla over valuation mismatch, market volatility, and differences over some agreement terms.
Akums Pharma, India's largest contract manufacturer plans European venture
Akums Drugs and Pharmaceuticals which recently received the European Union’s (EU’s) GMP stamp of approval for its two facilities in Haridwar is aiming to grow more in the European and American markets.
ICMR issues guidelines with warning for use of Antibiotics for Low-grade fever
The ICMR (Indian Council for Medical Research) has issued a warning against the use of antibiotics for illnesses such as low-grade fever and viral bronchitis and advising doctors to prescribe them with a timeline.
Akums Pharma receives approval from CDSCO panel to market Antihypertensive FDC drug
Indian drugmaker Akums pharma received nod from the Subject Matter Committee (SEC), functional under the CDSCO (Central Drugs Standard Contol Organization) to manufacture and market its new antihypertensive fixed dose combination drug.
SPMIG calls on NHS Scotland to make Genomic testing available for all Cancer Patients
The SPMIG (Scottish Precision Medicines Industry Group) set up by leading companies like AstraZeneca, Lilly, Novartis, and Roche has called upon NHS Scotland to make genomic testing available for every cancer patient in the country.
Only 1% of Emcure's Iron injections recalled by FDA returned to the manufacturer
Earlier this week, FDA recalled Emcure Pharmaceuticals Orofer FCM injection over a patient’s death after its administration, but only 1% out of 37,000 injections that are in the market has been returned to the manufacturer to date.
CDSCO tells Sandoz to review and report PSUR data of Brolucizumab injection
The Subject Expert Committee (SEC) under the CDSCO (Central Drug Standard Contol Organization) has suggested Sandoz to review and report the PSUR (Periodic Safety Update Reports) along with the Phase IV study report after the completion of studies for further evaluation.
